BACKGROUND: Rosacea is a common skin condition, but the currently available treatments are not satisfactory. OBJECTIVE: We wanted to assess the efficacy and safety of photopneumatic therapy (PPx), which delivers pneumatic energy and broadband light (400~1,200 nm), for the treatment of erythematotelangiectatic rosacea. METHODS: Twenty two patients with erythematotelangiectatic rosacea were treated 3~5 times with PPx. Three independent dermatologists evaluated the efficacy of PPx by comparing the photographs taken before and after treatment. Patient self-assessment was also done by interviews. RESULTS: The photographic assessment by the dermatologists of the improvement showed that >50% improvement occurred in 64% (14/22) of the patients. The specific categories of improvement were as follows: poor (<25% improvement), 1 patient; fair (25~50% improvement), 7 patients; good (50~75% improvement), 11 patients; and excellent (>75% improvement), 3 patients. Based on the patients' self-assessment, 20 patients (91%) acknowledged an improvement. CONCLUSION: PPx is an effective and safe treatment option for erythematotelangiectatic rosacea.
BACKGROUND:Rosacea is a common skin condition, but the currently available treatments are not satisfactory. OBJECTIVE: We wanted to assess the efficacy and safety of photopneumatic therapy (PPx), which delivers pneumatic energy and broadband light (400~1,200 nm), for the treatment of erythematotelangiectatic rosacea. METHODS: Twenty two patients with erythematotelangiectatic rosacea were treated 3~5 times with PPx. Three independent dermatologists evaluated the efficacy of PPx by comparing the photographs taken before and after treatment. Patient self-assessment was also done by interviews. RESULTS: The photographic assessment by the dermatologists of the improvement showed that >50% improvement occurred in 64% (14/22) of the patients. The specific categories of improvement were as follows: poor (<25% improvement), 1 patient; fair (25~50% improvement), 7 patients; good (50~75% improvement), 11 patients; and excellent (>75% improvement), 3 patients. Based on the patients' self-assessment, 20 patients (91%) acknowledged an improvement. CONCLUSION:PPx is an effective and safe treatment option for erythematotelangiectatic rosacea.
Authors: Jonathan Wilkin; Mark Dahl; Michael Detmar; Lynn Drake; Alvan Feinstein; Richard Odom; Frank Powell Journal: J Am Acad Dermatol Date: 2002-04 Impact factor: 11.527
Authors: Jonathan Wilkin; Mark Dahl; Michael Detmar; Lynn Drake; Matthew H Liang; Richard Odom; Frank Powell Journal: J Am Acad Dermatol Date: 2004-06 Impact factor: 11.527
Authors: Ali Rajabi-Estarabadi; Siri Choragudi; Isabella Camacho; Kevin J Moore; Jonette E Keri; Keyvan Nouri Journal: Lasers Med Sci Date: 2018-08-24 Impact factor: 3.161